Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Executive Summary
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
You may also be interested in...
Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: